Long-acting therapy of viral retinitis with (s)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine

Journal of Infectious Diseases

Volumn 169, Issue 3, 1994, Pages 642-647

  Aguilar, Marisa Flores ^a,b   Huang, Jen Shang ^a,b   Wiley, Gayton A ^a,b   Clercq, Erik De ^a,b   Vuong, Chau ^a,b   Bergeron Lynn, Germaine ^a,b   Chandler, Beverly ^a,b   Munguia, David ^a,b   Freeman, William R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; GANCICLOVIR;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; INTRAVITREAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; RETINITIS; VIRUS INFECTION;

ANIMAL; ANTIVIRAL AGENTS; CYTOSINE; DRUG THERAPY, COMBINATION; GANCICLOVIR; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; ORGANOPHOSPHORUS COMPOUNDS; RABBITS; RETINITIS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TIME FACTORS;

EID: 0028153740     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/169.3.642     Document Type: Article

References (15)

1. Freeman WR, Lemer CW, Mines JA, et al. A prospective study of the ophthalmologic findings in the acquired immune deficiency syndrome. Am J Ophthalmol 1984;97:133-42.
2. Henderly DE, Freeman WR, Causey DM, Rao NA. Cytomegalovirus retinitis and response to therapy with ganciclovir. Ophthalmology 1988;94:425-34.
3. Fanning MM, Read SE, Benson M, et al. Foscarnet therapy of cytomegalovirus retinitis in AIDS. J Acquir Immune Defic Syndr 1990;3:472-9.
4. Erice A, Chou S, Biron KK, Stanant SC, Balfour HH Jr, Jordan MC. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med 1989;320:389-91.
5. Flores-Aguilar M, Kuppermann BD, Quiceno JI, et al. Pathophysiology and treatment of clinically resistant cytomegalovirus retinitis. Ophthalmology 1993;100:1022-31.
6. Heinemann MH. Long-term intravitreal ganciclovir therapy for cytomegalovirus retinopathy. Arch Ophthalmol 1989;107:1767-72.
7. Snoeck R, Sakuma T, De Clercq E, Rosenberg I, Holy A. (S)-l-(3-hy-droxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother 1988;32:1839-44.
8. Shigeta S, Konno K, Baba M, Yokota T, De Clercq E. Comparative inhibitory effects of nucleoside analogues on different clinical isolates of human cytomegalovirus in vitro. 1991;163:270-5.
9. Neyts J, Snoeck R, Balzarini J, De Clercq E. Particular characteristics of the anti-human cytomegalovirus activity of (S)-l-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vitro. Antiviral Res 1991;16:41-52.
10. Dolnak DR, Munguia D, Wiley CA, et al. Lack of retinal toxicity of anti-CMV drug (S)-l-(3-hydroxy-2-phosphonylmethoxypropyl)cy-tosine. Invest Ophthalmol Vis Sci 1992;33:1557.
11. Freeman WR, Schneiderman TE, Wiley CA, et al. An animal model of focal, subacute, viral retinitis. Retina 1993;13:214-21.
12. Holland GN, Sakamoto MJ, Hardy D, Sidikaro Y, Kreiger AE, Frenkel LM. Treatment of cytomegalovirus retinopathy in patients with acquired immunodeficiency syndrome. Arch Ophthalmol 1986; 104: 1794-1800.
13. Yoshizumi M, Lee D, Vinci V, Fajardo S. Ocular toxicity of multiple intravitreal DHPG injections. Graefes Arch Clin Exp Ophthalmol 1990;228:350-5.
14. Sanborn GE, Anand R, Torti RE, et al. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Use of an intravitreal device. Arch Ophthalmol 1992; 110:188-95.
15. Neyts J, Snoeck R, Schols D, Balzarini J, De Clercq E. Selective inhibition of human cytomegalovirus DNA synthesis by Sj-l-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] and 9-(1, 3-di-hydroxy-2-propoxymethyl)guanine (DHPG). Virology 1990; 179: 41-50.